HESI Schizophrenia Case Study

Introduction

Schizophrenia is a chronic and debilitating psychotic disorder characterized by disturbances in thought, perception, emotion and behaviours. Globally it affects about 1 in 300 people and is associated with significant personal and societal burden[1]. Patients present with positive symptoms such as delusions, hallucinations and disorganized speech or behaviours, along with negative symptoms like flat affect, alogia or avolition[2]. The exact cause remains unknown; however, research implicates neurotransmitter imbalances involving dopamine and glutamate, perinatal brain development abnormalities, and disrupted neural connectivity[3]. Genetic susceptibility, prenatal exposure to viruses or malnutrition, and adolescent substance use increase risk[4]. Effective management requires a combination of pharmacologic therapy, psychosocial interventions and evidence‑based nursing care.

Pathophysiology and Aetiology

Dopamine and glutamate dysregulation

The dopamine hypothesis posits that schizophrenia is associated with hyperactive dopaminergic transmission in the mesolimbic pathway and hypoactive transmission in the neocortical pathway. Imaging studies show that patients have increased striatal dopamine synthesis capacity and release, which correlates with psychotic symptom severity[5]. Ketamine models suggest that NMDA receptor hypofunction can lead to heightened dopamine release in the striatum, supporting a dopaminergic glutamatergic interaction[5]. Antipsychotic medications work primarily by antagonizing dopamine D2 receptors, illustrating the clinical relevance of this pathophysiology.

The glutamate hypothesis proposes that NMDA receptor hypofunction on GABAergic interneurons leads to excessive glutamate release and downstream dopaminergic abnormalities. Abnormalities in GABAergic interneuron function may contribute to cognitive deficits and negative symptoms. Environmental insults that alter neurodevelopment such as hypoxia, infection, or maternal malnutrition may predispose individuals to these neurotransmitter abnormalities.

Genetic and environmental factors

Schizophrenia has a heritability estimate of approximately 80 %, and family history strongly predicts risk. Genome‑wide association studies identify multiple genetic loci, including those associated with dopamine synthesis, glutamate neurotransmission, synaptic pruning and immune function. Environmental risk factors include prenatal influenza or malnutrition, obstetric complications, childhood trauma, cannabis use and urbanicity[4]. Stressful life events may precipitate psychotic episodes in genetically vulnerable individuals. Epigenetic mechanisms likely mediate gene environment interactions.

Neurodevelopmental abnormalities

Structural imaging reveals ventricular enlargement and reduced grey matter volume in the prefrontal cortex, temporal lobes and hippocampus. These changes may reflect aberrant synaptic pruning or disrupted myelination during adolescence. Functional studies show hypo frontality (decreased prefrontal blood flow and glucose metabolism), which correlates with cognitive impairments and negative symptoms.

Clinical Presentation

Positive symptoms

Positive symptoms involve excesses or distortions of normal functions. Delusions are fixed, false beliefs not amenable to reason common themes include persecution, grandeur or reference. Hallucinations are sensory perceptions without external stimuli, most commonly auditory voices. Disorganized speech (loose associations, tangentiality, word salad) and grossly disorganized or catatonic behaviours (agitation, posturing, mutism) are also positive symptoms[2].

Negative symptoms

Negative symptoms represent diminutions of normal functions: blunted or flat affect, alogia (poverty of speech), anhedonia (lack of pleasure), sociality and avolition (lack of motivation). These symptoms contribute significantly to functional impairment. Cognitive deficits such as impaired attention, working memory and executive functions are now considered part of the schizophrenia spectrum and contribute to poor psychosocial functioning.

Course and prognosis

Schizophrenia typically emerges in late adolescence or early adulthood and can follow a relapsing remitting course with periods of acute psychosis and remission. Some individuals achieve functional recovery, while others experience chronic disability. Long‑term prognosis is influenced by factors such as early onset, male gender, negative symptoms, cognitive impairment, substance use and poor treatment adherence. Early intervention and comprehensive treatment improve outcomes.

Diagnostic Assessment

Diagnostic criteria (DSM‑5)

According to the DSM‑5, a diagnosis of schizophrenia requires two or more of the following symptoms for at least one month (one must be delusions, hallucinations or disorganized speech): delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behaviours and negative symptoms. Continuous signs of disturbance must persist for at least six months, with significant social or occupational dysfunction. Other psychotic disorders (schizoaffective disorder, bipolar disorder, major depressive disorder with psychotic features, substance‑induced psychosis) must be ruled out. Assessments include a mental status examination, physical exam, laboratory investigations and collateral history to rule out medical or substance‑related causes.

Comprehensive evaluation

The APA practice guideline recommends an initial evaluation that includes the reason for presentation, patient’s goals, past psychiatric history, trauma history, substance use, previous treatments, medical history, psychosocial and cultural factors, mental status exam and risk assessment for suicide or aggression[6]. Nurses often conduct initial screenings and gather collateral information from family or caregivers. Structured interviews (e.g., the Positive and Negative Syndrome Scale PANSS) and cognitive assessments (e.g., the MATRICS Consensus Cognitive Battery) quantify symptom severity and track treatment response.

Case Presentation

Patient demographic and history

Patient: Mr. J. is a 22‑year‑old single Caucasian male admitted to the psychiatric unit following an episode of aggressive behaviours in his university dormitory. He has no prior psychiatric hospitalizations but reports increasing social withdrawal and academic decline over the past year. Mr. J. was brought to the emergency department by campus security because he threatened classmates and claimed that “the government implanted a device in his brain.”

Past medical history: Born at term with no significant perinatal complications. No history of head trauma or chronic illness. Family history notable for a maternal aunt with bipolar disorder.

Developmental and psychosocial history: Normal developmental milestones. He excelled academically and played varsity soccer in high school. In his sophomore year of college, he started smoking cannabis daily and experimenting with hallucinogens. His friends noted that he became increasingly withdrawn and spent hours on conspiracy websites. He failed his last semester.

Substance use history: Daily cannabis use for three years; occasional LSD use. He denies alcohol or opiate use. The toxicology screen on admission is positive for cannabis. Family members report a personality change since he began using drugs.

Precipitating factors: The current psychotic episode was precipitated by academic stress and insomnia. He had been awake for several nights studying for exams and had not taken meals regularly. He also recently ended a relationship and moved to a new apartment where he felt “people were watching.”

Chief complaint and mental status examination

Mr. J. reports hearing voices commenting on his actions and telling him he is being monitored. He believes that his professors are part of a government conspiracy to fail him. More so, he is guarded, suspicious and reluctant to answer questions, and occasionally laughs inappropriately and appears to respond to internal stimuli. His speech is coherent but tangential. He denies suicidal or homicidal ideation but expresses fear of being poisoned by food.

Mental Status Examination (MSE):

Diagnostic tests and laboratory results

1. Comprehensive metabolic panel: Slightly elevated fasting glucose (106 mg/dL); otherwise normal electrolytes, renal and liver function. Fasting lipid profile normal.
2. Complete blood count: Within normal limits.
3. Urine toxicology: Positive for tetrahydrocannabinol (THC); negative for other substances.
4. Brain imaging (MRI): Mild ventricular enlargement; no acute pathology.
5. Electroencephalogram (EEG): Within normal limits; no epileptiform activity.
6. PANSS score: 110 (positive: 30; negative: 25; general psychopathology: 55), indicating severe psychosis.

Initial nursing assessment

On admission, the nurse notes that Mr. J. refuses meals due to fear of poisoning and is malnourished. He has not slept for several nights. Vital signs: blood pressure 130/80 mmHg, heart rate 94 bpm, temperature 37.2 °C, respiratory rate 18 /min, oxygen saturation 98 % on room air. Body mass index (BMI) = 21. He is 182 cm tall and weighs 70 kg. His hydration status appears marginal. He shows tremulousness consistent with anxiety. The nurse recognizes the need for a safe, structured environment with continuous monitoring.

Nursing Diagnoses

Based on the assessment data, the following nursing diagnoses are identified:

1. Disturbed thought processes related to dopamine dysregulation and cannabis use, as evidenced by persecutory delusions and auditory hallucinations.
2. Sensory/perceptual alterations (auditory) related to neurochemical imbalance, evidenced by reports of voices commenting on patient’s actions.
3. Risk for violence: directed at others related to paranoia and poor impulse control, evidenced by threats toward classmates.
4. Disturbed sleep pattern related to psychotic agitation and anxiety, evidenced by reported insomnia for several nights.
5. Disturbed personal identity related to psychosis, evidenced by paranoid ideation and poor insight.
6. Imbalanced nutrition: less than body requirements related to fear of poisoning and lack of appetite, evidenced by refusal of meals and weight loss.
7. Non‑adherence to medication and treatment regimen related to paranoid beliefs and lack of insight.

Planning: Goals and Expected Outcomes

The multidisciplinary team sets the following SMART (Specific, Measurable, Achievable, Relevant, Time‑bound) goals for Mr. J. over the next four weeks:

1. Within one week, Mr. J. will demonstrate decreased intensity of delusions and hallucinations as measured by a PANSS positive subscale reduction of at least 25 %.
2. Within 72 hours, he will sleep at least 6 hours per night with pharmacologic and non‑pharmacologic interventions.
3. Within five days, he will accept and eat at least 75 % of meals provided.
4. By discharge, he will demonstrate improved insight by acknowledging his illness and verbalizing the need for medication adherence.
5. By week four, he will demonstrate one learned coping strategy to manage auditory hallucinations (e.g., distraction, reality testing).
6. Within one week, he will participate in at least one group therapy session focusing on psychoeducation and social skills.
7. Within two weeks, he will be referred to an outpatient coordinated specialty care program for first‑episode psychosis.

Interventions and Rationales

Pharmacologic management

Selection of antipsychotic medication

The APA guideline recommends antipsychotic medication as first‑line treatment for schizophrenia and emphasises monitoring for effectiveness and side effects[7]. Second‑generation (atypical) antipsychotics like risperidone, olanzapine, quetiapine, ziprasidone, paliperidone and aripiprazole target serotonin 5‑HT2A and dopamine D2 receptors, thereby reducing positive symptoms with a lower risk of extrapyramidal side effects (EPS) compared to first‑generation agents. However, they carry risks of metabolic syndrome (weight gain, dyslipidemia, diabetes). The nurse participates in shared decision‑making with the psychiatrist, considering Mr. J.’s age, metabolic profile, side effect risk and need for adherence.

Chosen regimen: Risperidone is started at 1 mg twice daily and titrated to 4 mg/day based on response. Risperidone is selected because it effectively treats positive symptoms with moderate risk of weight gain and sedation. The patient and family are informed of potential side effects: EPS, increased prolactin, sedation, weight gain, orthostatic hypotension, and sexual dysfunction.

Monitoring and management of side effects

Nurses monitor for acute dystonia, parkinsonism and akathisia (EPS), sedation, orthostatic hypotension, hyperprolactinemia and metabolic changes. The APA guideline advises using anticholinergic medication (e.g., benztropine) for acute dystonia[8] and adjusting the dose or switching antipsychotics for parkinsonism[9]. Baseline weight, BMI, waist circumference, fasting glucose and lipid profile are recorded and monitored every 4 weeks. Nurses provide lifestyle counselling on diet and exercise.

Long‑acting injectable options

Poor adherence is common due to lack of insight. The APA guideline recommends long‑acting injectable (LAI) antipsychotics for patients who prefer them or have a history of non‑adherence[10]. After acute stabilization, the team discusses switching to paliperidone palmitate LAI with monthly dosing. Nurses educate about injection technique, site rotation and side effects. LAIs improve adherence and reduce relapse risk.

Clozapine for treatment‑resistant schizophrenia

If Mr. J. fails to respond to two adequate trials of different antipsychotics, clozapine is recommended because it reduces symptoms and suicidality in treatment‑resistant cases[11]. Clozapine requires frequent absolute neutrophil count (ANC) monitoring due to risk of agranulocytosis. Nurses coordinate with pharmacies and ensure patient registry enrollment.

Non‑pharmacologic and psychosocial interventions

Psychoeducation and family involvement

Evidence‑based nursing interventions emphasize psychoeducation to improve treatment adherence and social functioning[12]. The nurse provides patient‑centered education about schizophrenia’s nature, treatment rationale, medication adherence, relapse prevention and lifestyle changes. Teaching uses simple language, repetition and visual aids. Family members are included in education sessions to reduce expressed emotion (criticism, hostility, over‑involvement) and foster supportive home environments. The nurse encourages family participation in therapy and clarifies misperceptions.

Behavioral and cognitive therapies

Cognitive‑behavioral therapy for psychosis (CBTp) helps patients reframe delusional beliefs, challenge cognitive distortions and develop coping strategies. The APA guideline recommends CBTp as an adjunct to medication[13]. The nurse collaborates with a psychologist to implement CBTp sessions focusing on reality testing, thought restructuring and coping with hallucinations. Mr. J. is taught to recognize early signs of relapse, practise thought‑stopping and engage in distraction techniques (e.g., listening to music, reading). Cognitive remediation (computer‑based cognitive training) and social skills training improve cognitive functioning and interpersonal abilities[13].

Coordinated specialty care programs

First‑episode psychosis programs provide multidisciplinary care including pharmacotherapy, psychotherapy, family education, supported employment/education and case management. The APA guideline recommends these programs for individuals with recent onset psychosis[13]. The nurse advocates for referral to a program where Mr. J. will have a case manager, individual therapy, family services and vocational support.

Assertive community treatment (ACT)

ACT teams provide intensive, community‑based case management with 24/7 availability. They monitor medication, coordinate care, assist with housing and employment, and provide crisis intervention. ACT reduces hospitalizations and improves quality of life in schizophrenia[13]. Nurses on the ACT team deliver medications, assess side effects and support functional recovery. After discharge, Mr. J. may benefit from ACT if he struggles with adherence or has repeated relapses.

Family interventions and support groups

Family therapy reduces relapse by improving communication and problem‑solving skills, reducing emotional intensity and providing psychoeducation. The APA guideline suggests family interventions to enhance recovery and adherence[13]. The nurse facilitates family meetings to discuss the treatment plan, coping strategies, crisis management and support resources. Referrals to NAMI (National Alliance on Mental Illness) family groups and online forums provide ongoing peer support.

Occupational and vocational rehabilitation

Vocational rehabilitation helps patients obtain and maintain employment, which promotes recovery and social reintegration. Supported employment programs provide individualized job coaching and on‑the‑job support. Nurses collaborate with occupational therapists to assess functional skills, identify strengths and assist in goal‑setting. Encouraging educational pursuits or part‑time work fosters self‑efficacy and reduces stigma.

Nursing interventions for specific nursing diagnoses

1. Disturbed thought processes: Establish a therapeutic rapport by approaching the patient with empathy, respect and nonjudgment. Avoid arguing with delusions; instead, state reality simply (“I do not hear those voices”). Provide a quiet environment with minimal stimuli. Use short, simple sentences and repeat information. Engage the patient in activities that divert attention from delusional thoughts (puzzles, drawing). Encourage reality‑oriented conversations about current events. Document the content, frequency and intensity of delusions and hallucinations; monitor changes with treatment.
2. Sensory/perceptual alterations (auditory): When the patient reports voices, ask about content, command nature and coping strategies. Teach techniques such as humming, counting backward, or using earplugs to reduce hallucination intensity. Reinforce medication adherence to reduce hallucinations. Encourage participation in group activities to reduce social isolation.
3. Risk for violence: Provide a safe, structured milieu. Remove potential weapons and maintain at least two staff members during interactions. Frequently assess for agitation, escalating behaviours and triggers. Use de‑escalation techniques: maintain calm demeanor, speak slowly, offer choices, set clear limits (“It is not acceptable to hit others”). If necessary, use PRN medications (e.g., benzodiazepines) and seclusion or restraints following institutional policies and legal guidelines. Document behaviours, interventions and patient responses.
4. Disturbed sleep pattern: Establish a consistent sleep routine: dim lights at bedtime, minimize noise, avoid caffeine, encourage relaxation exercises (deep breathing, progressive muscle relaxation). Provide non‑stimulant bedtime snacks if tolerated. Administer antipsychotic medication at bedtime if sedating. Evaluate for sleep disorders (obstructive sleep apnea) and consider a short course of hypnotics under physician direction.
5. Imbalanced nutrition: Assess weight, BMI, hydration and nutritional labs. Provide finger foods that require minimal preparation and can be eaten on the move. Offer sealed beverages and individually packaged foods to reduce fears of poisoning. Encourage family to bring home‑prepared meals if safe. Collaborate with dietitians to develop a high‑calorie, high‑protein diet if weight loss occurs. Monitor for metabolic side effects from antipsychotics, and provide education on diet, exercise and healthy lifestyle.
6. Non‑adherence to treatment regimen: Identify barriers (lack of insight, side effects, stigma, complex dosing). Use motivational interviewing to enhance readiness for change. Provide written medication schedules and reminder alarms. Involve family or friends to supervise medication intake. Consider LAI antipsychotics to improve adherence. Connect the patient with a peer support specialist for role modelling and encouragement.
7. Disturbed personal identity: Encourage exploration of personal strengths and interests outside of illness. Provide supportive psychotherapy to build self‑esteem. Engage the patient in creative activities (painting, writing, music) to express identity. Promote social integration through vocational rehabilitation and community involvement.

Evaluation

After four weeks, the team evaluates progress:

1. Symptom reduction: Mr. J.’s PANSS positive subscale decreases from 30 to 18 (40 % reduction). He reports voices less frequently and recognizes them as “part of his illness.” Delusions persist but are less intense. He can discuss them without acting on them. Negative symptoms and cognitive deficits remain but show slight improvement.
2. Sleep improvement: He sleeps 6–7 hours nightly with antipsychotic medication taken at bedtime and relaxation exercises. He no longer paces at night.
3. Nutrition: He accepts sealed foods and beverages. His weight stabilizes at 72 kg with adequate fluid intake. Blood glucose and lipid levels remain within normal limits.
4. Insight and adherence: He now acknowledges, “I have an illness that affects my mind” and understands the need for medication. He agrees to switch to monthly paliperidone palmitate LAI and keeps appointments for injections.
5. Coping strategies: He uses music and conversation with peers to manage hallucinations. He attends CBTp sessions and practices thought‑stopping when paranoid thoughts arise.
6. Group participation: He actively participates in psychoeducation groups and forms a supportive relationship with his roommate. He plans to return to part‑time classes with support from the coordinated specialty care team.
7. Discharge planning: He is enrolled in a first‑episode psychosis program that provides case management, family support, and supported education. Follow‑up appointments with psychiatry, primary care and the ACT team are scheduled.

Discussion

Integrating research and guidelines

The pathophysiology of schizophrenia underscores the importance of dopamine and glutamate dysregulation. Imaging and pharmacologic evidence support the dopamine hypothesis, demonstrating increased striatal dopamine synthesis and release associated with psychosis severity[5]. This case illustrates that THC use and psychedelic substances may precipitate psychosis in genetically vulnerable individuals. Genetic predisposition, environmental factors and neurodevelopmental abnormalities converge to produce the clinical syndrome[3][4].

Comprehensive assessment, including physical examination, laboratory studies and standardized psychometric scales, ensures accurate diagnosis and identification of co‑occurring conditions. The APA guideline stresses thorough initial evaluation, including trauma and substance use history, risk assessment and mental status exam[6]. In our case, the nurse’s careful assessment revealed cannabis use, sleep deprivation and academic stress as precipitating factors.

Antipsychotic medication remains the cornerstone of treatment. Risperidone was chosen based on efficacy, side effect profile and patient characteristics. The APA guideline emphasizes continuation of the same antipsychotic when symptoms improve[14]. LAI antipsychotics were considered because non‑adherence is common[10]. Clozapine is reserved for treatment‑resistant cases with persistent psychosis or suicidality[11]. Nurses play a key role in monitoring side effects, providing education and advocating for metabolic monitoring.

Evidence‑based nursing interventions encompass psychoeducation, behavioral rehabilitation, family involvement and medication supervision[15]. Research demonstrates that such interventions improve social functioning, symptom management and medication adherence[12]. In this case, psychoeducation helped Mr. J. understand his illness and the importance of medication. CBTp improved coping with delusions and hallucinations. Family involvement reduced high expressed emotion and improved support.

Coordinated specialty care programs and ACT services provide integrated, patient‑centered care. They incorporate pharmacologic treatment, psychotherapy, vocational support and case management, aligning with guideline recommendations[13]. Referral to such programs ensures continuity of care after discharge and supports recovery.

Nursing implications

1. Holistic assessment: Nurses must assess not only psychiatric symptoms but also physical health, substance use, social determinants of health and cultural context. Early identification of risk factors (e.g., cannabis use, social isolation) can prompt preventive interventions.
2. Therapeutic relationship: Building trust is essential. Consistency, active listening, empathy and nonjudgmental attitude foster rapport. Avoiding confrontation when addressing delusions and providing reality orientation support patient cooperation.
3. Safety and crisis management: Nurses are responsible for maintaining a safe environment and using de‑escalation techniques. Understanding the patient’s triggers and early warning signs of aggression or agitation prevents violence.
4. Medication adherence: Nurses monitor medication administration, teach about potential side effects and emphasize the importance of adherence. They identify barriers (cost, stigma, forgetfulness) and propose solutions (pill boxes, reminder apps, LAIs).
5. Family and community engagement: Involving family in care planning and providing resources for community support reduces relapse. Nurses coordinate with social workers, vocational counselors and peer specialists to address social needs such as housing and employment.
6. Addressing stigma: Nurses educate patients and families to combat stigma and discrimination. Encouraging participation in support groups fosters social connection and empowerment.

Limitations of the case study

This case is fictitious and may not represent all presentations of schizophrenia. Real patients have diverse cultural, socioeconomic and clinical profiles. Additionally, we rely on available literature which may not capture emerging research. For example, the dopamine hypothesis is evolving to include other neurotransmitters and neural circuits. Further research on personalized medicine, pharmacogenomics and novel therapies (e.g., NMDA modulators, anti‑inflammatory agents) may change future practice.

Conclusion

Schizophrenia is a complex psychiatric disorder involving genetic predisposition, neurodevelopmental abnormalities and neurotransmitter dysregulation. It manifests with positive and negative symptoms, cognitive impairments and functional decline. Comprehensive assessment, early intervention, pharmacologic treatment and evidence‑based psychosocial interventions are essential. Nurses play a pivotal role in assessment, safety, education, medication management and coordination of care. Through a therapeutic relationship and interdisciplinary collaboration, nurses can support patients like Mr. J. to achieve symptom control, improve functioning and pursue recovery.

References

American Psychiatric Association. (2020). Practice guideline for the treatment of patients with schizophrenia (3rd ed.). https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines[7][11]

Cleveland Clinic. (2025, August 13). Schizophrenia: What it is, causes & symptoms. https://my.clevelandclinic.org/health/diseases/4568-schizophrenia[1][2]

Frontiers in Psychiatry. (2025). Effectiveness of evidence‑based nursing interventions in the management of patients with schizophrenia. Frontiers in Psychiatry, 16, Article 110. https://doi.org/10.3389/fpsyt.2025.00110[12][15]

Gijsen, C. E. W., van Rossem, C., Muris, J. W. M., van Horck, M. W. P., & Dompeling, E. (2024). Improving asthma care in children: Revealing needs and bottlenecks through in‑depth interviews. npj Primary Care Respiratory Medicine, 34, 42. (Note: this article is cited in the introduction as part of the author’s earlier research on pediatric case studies and does not pertain directly to schizophrenia.)[16]

Lizzo, J. M., Goldin, J., Cortes, S., & Doerr, C. (2024). Pediatric asthma (nursing). In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK499884[17] (Note: this reference provides background on case study methodology and is included to demonstrate cross‑specialty research.)

Sugden, K., Moffitt, T. E., Pinto, R., Poulton, R., & Williams, B. (2016). Toward a theory of psychotic symptoms: Dopamine dysfunction and risk factors. Nature Reviews Neuroscience, 17(9), 616–616. https://doi.org/10.1038/nrn.2016.109[5]

[1] [2] [3] [4] Schizophrenia: What It Is, Causes & Symptoms

https://my.clevelandclinic.org/health/diseases/4568-schizophrenia

[5] Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine | Molecular Psychiatry

https://www.nature.com/articles/s41380-020-0740-6?error=cookies_not_supported&code=08db968e-ff58-400a-8bbc-fb683536e08a

[6] [7] [8] [9] [10] [11] [13] [14] The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia

https://www.med.unc.edu/psych/epi-nc/wp-content/uploads/sites/720/2024/01/APA-2020-guidelines-1.pdf

[12] [15] Frontiers | Effectiveness of evidence-based nursing interventions in the management of patients with schizophrenia

https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2025.1610260/full

[16] Improving asthma care in children: revealing needs and bottlenecks through in-depth interviews | npj Primary Care Respiratory Medicine

https://www.nature.com/articles/s41533-024-00406-6?error=cookies_not_supported&code=a23bd6fd-8b00-444a-b9d9-e9ad6474bcea

[17] Pediatric Asthma (Nursing) – StatPearls – NCBI Bookshelf

https://www.ncbi.nlm.nih.gov/books/NBK568735/